✦ LIBER ✦

Magna-field irradiation and autologous marrow rescue in the treatment of pediatric solid tumors

✍ Scribed by Louis L. Munoz; Moody D. Wharam; Herbert Kaizer; Brigid G. Leventhal; Frederick Ruymann

Publisher: Elsevier Science
Year: 1983
Tongue: English
Weight: 510 KB
Volume: 9
Category: Article
ISSN: 0360-3016
DOI: 10.1016/0360-3016(83)90367-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Autologous bone marrow rescue in the tre

Autologous bone marrow rescue in the treatment of advanced tumors of childhood

✍ Henry Ekert; W. Mary Ellis; Keith D. Waters; Geoffrey P. Tauro 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 543 KB

Autologous bone marrow transplantation i

Autologous bone marrow transplantation in the treatment of children and adolescents with advanced malignant tumors

✍ Baumgartner, Christoph ;Bleher, E. Arnold ;del Re, Guido Brun ;Bucher, Urs ;Deub 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 751 KB

Nineteen patients with advanced malignant tumors, less than 20 years old were treated with intensive chemotherapy (vincristine 2 mg/m2 i.v. and adriamycin 60 mg/m2 i.v. on day - 7; cyclophosphamide 45 mg/kg i.v. on days -6 to -3), total body irradiation (TBI, 600 rads on day -1) and autologous bone

The potential value of very intensive th

The potential value of very intensive therapy with autologous bone marrow rescue in the treatment of malignant lymphomas

✍ J. G. Gribben; Dr B. Vaughan Hudson; D. C. Linch 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 821 KB

Autologous bone marrow transplantation (ABMT) following intensive therapy regimes is being used increasingly in relapsed lymphomas. To date no randomised studies have been performed to ascertain the value of this form of therapy. We describe here our experience of ABMT in both Hodgkin's disease and

Aziridinylbenzoquinone (AZQ) in the trea

Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors

✍ R. P. Castleberry; A. H. Ragab; C. P. Steuber; B. Kamen; S. Toledano; K. Starlin 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 445 KB

To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given ov

Salvage therapy with high-dose chemother

Salvage therapy with high-dose chemotherapy and autologous bone marrow support in the treatment of primary nonseminomatous mediastinal germ cell tumors

✍ E. R. Broun; C. R. Nichols; L. H. Einhorn; G. J. K. Tricot 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 268 KB 👁 2 views

5-fluorouracil and cis-platinum in the t

5-fluorouracil and cis-platinum in the treatment of refractory solid tumors: A pediatric oncology group phase I — II study

✍ Land, Vita J. ;Dyment, Paul G. ;Starling, Kenneth ;Strandjord, Sarah E. ;Chan, R 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB

## Abstract Eleven patients with osteogenic sarcoma (9), Hodgkin disease (1), and mesenchymal sarcoma (1), were treated with 5‐fluorouracil (5‐FU) and cisplatin (DDP). Myelosuppression and vomiting of variable degrees occurred in all. No responses were seen.